SCHEMBL2572180

SCHEMBL2572180

CC(=O)c1ccccc1N(C)Cc1ccc(Cl)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FSCN1 Q16658 1/20 0.43
PYCR1 P32322 1/20 0.43
HTT P42858 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CYP1A2 P05177 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
CYP3A4 P08684 1/20 0.41
ALDH1A1 P00352 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 2/20 0.41
ERCC1 P07992 1/20 0.41
ERCC4 Q92889 1/20 0.41
GAA P10253 1/20 0.40
TMEM97 Q5BJF2 2/20 0.40
SIGMAR1 Q99720 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9824373 0.76 FSCN1 (0.53) FSCN1PYCR1HTTNPSR1CYP1A2
SCHEMBL2572183 0.76 PYCR1 (0.43) PYCR1HTTNPSR1CYP1A2CYP2D6
SCHEMBL11003393 0.73 PYCR1 (0.51) PYCR1HTTNPSR1CYP1A2CYP2D6
SCHEMBL9824901 0.71 FABP3 (0.64) CYP1A2CYP2D6CYP2C9CYP2C19TDP1
SCHEMBL26423790 0.71 TSHR (0.47) CYP3A4ALDH1A1KMT2AMAPTGAA
SCHEMBL5644342 0.70 SLC6A2 (0.55) PYCR1MEN1KMT2AMAPTERCC1
SCHEMBL31107315 0.70 PYCR1 (0.51) FSCN1PYCR1HTTNPSR1CYP2D6
SCHEMBL16553471 0.69 PYCR1 (0.61) PYCR1NPSR1CYP1A2CYP2D6CYP2C9
SCHEMBL2572182 0.69 HTT (0.51) PYCR1HTTNPSR1CYP1A2CYP2D6
SCHEMBL5915695 0.68 SLC6A4 (0.51) CYP1A2CYP2D6CYP2C9CYP2C19TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2384318-A2 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS Ardelyx, Inc. (US) 2011-11-09 EP disclosed
WO-2010078449-A2 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS ARDELYX, INC. (US) 2010-07-08 WO disclosed